Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;41(5):1016-24.
doi: 10.3899/jrheum.131313. Epub 2014 Mar 1.

Updating the OMERACT filter: implications for imaging and soluble biomarkers

Maria-Antonietta D'Agostino  1 , Maarten Boers, John Kirwan, Désirée van der Heijde, Mikkel Østergaard, Georg Schett, Robert B Landewé, Walter P Maksymowych, Esperanza Naredo, Maxime Dougados, Annamaria Iagnocco, Clifton O Bingham 3rd, Peter M Brooks, Dorcas E Beaton, Frederique Gandjbakhch, Laure Gossec, Francis Guillemin, Sarah E Hewlett, Margreet Kloppenburg, Lyn March, Philip J Mease, Ingrid Moller, Lee S Simon, Jasvinder A Singh, Vibeke Strand, Richard J Wakefield, George A Wells, Peter Tugwell, Philip G Conaghan
Affiliations

Updating the OMERACT filter: implications for imaging and soluble biomarkers

Maria-Antonietta D'Agostino et al. J Rheumatol. 2014 May.

Abstract

Objective: The Outcome Measures in Rheumatology (OMERACT) Filter provides a framework for the validation of outcome measures for use in rheumatology clinical research. However, imaging and biochemical measures may face additional validation challenges because of their technical nature. The Imaging and Soluble Biomarker Session at OMERACT 11 aimed to provide a guide for the iterative development of an imaging or biochemical measurement instrument so it can be used in therapeutic assessment.

Methods: A hierarchical structure was proposed, reflecting 3 dimensions needed for validating an imaging or biochemical measurement instrument: outcome domain(s), study setting, and performance of the instrument. Movement along the axes in any dimension reflects increasing validation. For a given test instrument, the 3-axis structure assesses the extent to which the instrument is a validated measure for the chosen domain, whether it assesses a patient-centered or disease-centered variable, and whether its technical performance is adequate in the context of its application. Some currently used imaging and soluble biomarkers for rheumatoid arthritis, spondyloarthritis, and knee osteoarthritis were then evaluated using the original OMERACT Filter and the newly proposed structure. Breakout groups critically reviewed the extent to which the candidate biomarkers complied with the proposed stepwise approach, as a way of examining the utility of the proposed 3-dimensional structure.

Results: Although there was a broad acceptance of the value of the proposed structure in general, some areas for improvement were suggested including clarification of criteria for achieving a certain level of validation and how to deal with extension of the structure to areas beyond clinical trials.

Conclusion: General support was obtained for a proposed tri-axis structure to assess validation of imaging and soluble biomarkers; nevertheless, additional work is required to better evaluate its place within the OMERACT Filter 2.0.

Keywords: BIOMARKERS; IMAGING; OMERACT FILTER; OUTCOME AND PROCESS ASSESSMENT; VALIDATION FRAMEWORK.

PubMed Disclaimer

Similar articles

  • Updating the OMERACT filter: core areas as a basis for defining core outcome sets.
    Kirwan JR, Boers M, Hewlett S, Beaton D, Bingham CO 3rd, Choy E, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Guillemin F, Gossec L, van der Heijde DM, Kloppenburg M, Kvien TK, Landewé RB, Mackie SL, Matteson EL, Mease PJ, Merkel PA, Ostergaard M, Saketkoo LA, Simon L, Singh JA, Strand V, Tugwell P. Kirwan JR, et al. J Rheumatol. 2014 May;41(5):994-9. doi: 10.3899/jrheum.131309. Epub 2014 Mar 15. J Rheumatol. 2014. PMID: 24634204 Free PMC article.
  • Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity.
    Tugwell P, Boers M, D'Agostino MA, Beaton D, Boonen A, Bingham CO 3rd, Choy E, Conaghan PG, Dougados M, Duarte C, Furst DE, Guillemin F, Gossec L, Heiberg T, van der Heijde DM, Hewlett S, Kirwan JR, Kvien TK, Landewé RB, Mease PJ, Østergaard M, Simon L, Singh JA, Strand V, Wells G. Tugwell P, et al. J Rheumatol. 2014 May;41(5):1000-4. doi: 10.3899/jrheum.131310. Epub 2014 Apr 1. J Rheumatol. 2014. PMID: 24692531 Free PMC article.
  • Updating the OMERACT filter: discrimination and feasibility.
    Wells G, Beaton DE, Tugwell P, Boers M, Kirwan JR, Bingham CO 3rd, Boonen A, Brooks P, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Gossec L, Guillemin F, Helliwell P, Hewlett S, Kvien TK, Landewé RB, March L, Mease PJ, Ostergaard M, Simon L, Singh JA, Strand V, van der Heijde DM. Wells G, et al. J Rheumatol. 2014 May;41(5):1005-10. doi: 10.3899/jrheum.131311. Epub 2014 Apr 1. J Rheumatol. 2014. PMID: 24692522 Free PMC article.
  • How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
    Boers M, Kirwan JR, Gossec L, Conaghan PG, D'Agostino MA, Bingham CO 3rd, Brooks PM, Landewé R, March L, Simon L, Singh JA, Strand V, Wells GA, Tugwell P. Boers M, et al. J Rheumatol. 2014 May;41(5):1025-30. doi: 10.3899/jrheum.131314. Epub 2014 Mar 1. J Rheumatol. 2014. PMID: 24584913
  • Updating the OMERACT filter: implications for patient-reported outcomes.
    Kirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, Choy E, de Wit M, Guillemin F, Hewlett S, Kvien TK, Landewé RB, Leong AL, Lyddiatt A, March L, May J, Montie PL, Nikaï E, Richards P, Voshaar MM, Smeets W, Strand V, Tugwell P, Gossec L. Kirwan JR, et al. J Rheumatol. 2014 May;41(5):1011-5. doi: 10.3899/jrheum.131312. Epub 2014 Mar 1. J Rheumatol. 2014. PMID: 24584919
See all similar articles

Cited by

References

    1. Thornbury JR. Eugene W. Caldwell Lecture. Clinical efficacy of diagnostic imaging: love it or leave it. AJR Am J Roentgenol. 1994;162(1):1–8. - PubMed
    1. Lassere MN. Imaging: the need for standardization. Best Pract Res Clin Rheumatol. 2008;22(6):1001–18. - PubMed
    1. Fineberg HV, Bauman R, Sosman M. Computerized cranial tomography. Effect on diagnostic and therapeutic plans. JAMA. 1977;238(3):224–7. - PubMed
    1. Boers M, Brooks P, Strand V, Tugwell P. The OMERACT Filter for outcome measures in rheumatology. J Rheumatol. 1998;25:198–9. - PubMed
    1. Boers M, Kirwan JR, Wells G, et al. A Framework and Process to Develop Core Outcome Sets: OMERACT Filter 2.0. In preparation.

Publication types

MeSH terms